This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (53)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Choroidal Neovascularization  • Macular Degeneration  • Retinal/ Chorioretinal Disorders  • Randomized Controlled Trial  • Alert me on articles by topic  Social Bookmarking   What's this?

Three-Year Results of an Open-Label Extension of 2 Randomized Clinical Trials—TAP Report No. 5

Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group

Arch Ophthalmol. 2002;120:1307-1314.

Objective  To report vision and safety outcomes from an extension of a 2-year investigation evaluating verteporfin photodynamic therapy in patients with age-related macular degeneration with subfoveal choroidal neovascularization (CNV).

Design and Setting  Open-label extension of selected patients from 2 multicenter, double-masked, placebo-controlled, randomized clinical trials, the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Investigation, at 22 ophthalmology practices in Europe and North America.

Participants  Patients enrolled in the TAP Investigation and followed up for at least 24 months in whom verteporfin therapy to CNV might reduce the risk of further vision loss.

Methods  Before receiving verteporfin therapy in the extension, eligible patients signed a written informed consent form accompanied by an oral consent process approved by local institutional review boards. Methods were similar to those described for 1- and 2-year results, with follow-up examinations beyond 2 years continuing at 3-month intervals with a few exceptions, including that extension patients with fluorescein leakage from CNV were to receive open-label verteporfin therapy irrespective of their original treatment assignment.

Results  Of 402 patients in the verteporfin group, 351 (87.3%) completed the month 24 examination; 320 (91.2%) of these enrolled in the extension study. The enrolled participants included 124 (78.0%) of the 159 verteporfin-treated patients with lesions composed of predominantly classic CNV at baseline, of whom 105 (84.7%) completed the month 36 examination. Verteporfin-treated patients with this lesion composition at baseline who participated in the extension study, with or without a month 36 examination, appeared more likely to have a younger age, better level of visual acuity, absence of fluorescein leakage from classic CNV, or no progression of classic CNV beyond the baseline boundaries of the lesion at the month 24 examination compared with those who did not enroll in the extension. For the 105 patients with a predominantly classic baseline lesion composition who completed the month 36 examination, an average of 1.3 treatments were given from the month 24 examination up to, but not including, the month 36 examination. A letter score loss in the study eye of at least 15 from baseline for these patients occurred in 39 (37.5%) at the month 24 examination compared with 44 (41.9%) of these patients at the month 36 examination. Visual acuity changed little from the month 24 examination (mean, -1.9 lines) to the month 36 examination (mean, -2.0 lines) for these eyes. Verteporfin-treated patients had little change in the mean visual acuity lost and few or no additional instances of infusion-related back pain or photosensitivity reactions from month 24 to month 36. Two patients originally assigned to placebo had acute severe vision decrease within 7 days after verteporfin treatment during the extension. One patient originally assigned to verteporfin had acute severe vision decrease after verteporfin treatment of the fellow eye during the extension.

Conclusions  Vision outcomes for verteporfin-treated patients with predominantly classic lesions at baseline remained relatively stable from month 24 to month 36, although only approximately one third of the verteporfin-treated patients originally enrolled with this lesion composition had a month 36 examination. From these results, the TAP Study Group identified no safety concerns to preclude repeating photodynamic therapy with verteporfin. Additional treatment was judged likely to reduce the risk of further vision loss. Caution appears warranted in the absence of comparison with an untreated group during the extension and since not all patients in the TAP Investigation participated in the TAP Extension.

A complete list of the participants in the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy Study Group was published in Arch Ophthalmol. 1999;117:1343-1344, with updates in Arch Ophthalmol. 2001;119:206.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Screening Older Adults for Impaired Visual Acuity: A Review of the Evidence for the U.S. Preventive Services Task Force
Chou et al.
ANN INTERN MED 2009;151:44-58.
ABSTRACT | FULL TEXT  

Observational prospective study of the effectiveness in routine clinical practice of verteporfin photodynamic therapy in patients with neovascular age-related macular degeneration
Murjaneh et al.
Br J Ophthalmol 2009;93:468-473.
ABSTRACT | FULL TEXT  

Photoreceptor Protection after Photodynamic Therapy Using Dexamethasone in a Rat Model of Choroidal Neovascularization
She et al.
IOVS 2008;49:5008-5014.
ABSTRACT | FULL TEXT  

Drug Delivery to Posterior Intraocular Tissues: Third Annual ARVO/Pfizer Ophthalmics Research Institute Conference
Edelhauser et al.
IOVS 2008;49:4712-4720.
FULL TEXT  

Evaluation of the New Photosensitizer Stakel (WST-11) for Photodynamic Choroidal Vessel Occlusion in Rabbit and Rat Eyes
Berdugo et al.
IOVS 2008;49:1633-1644.
ABSTRACT | FULL TEXT  

Simultaneous but Not Prior Inhibition of VEGF165 Enhances the Efficacy of Photodynamic Therapy in Multiple Models of Ocular Neovascularization
Ju et al.
IOVS 2008;49:662-670.
ABSTRACT | FULL TEXT  

Intravitreal Bevacizumab vs Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration
Bashshur et al.
Arch Ophthalmol 2007;125:1357-1361.
ABSTRACT | FULL TEXT  

Reduced Photoreceptor Damage after Photodynamic Therapy through Blockade of Nitric Oxide Synthase in a Model of Choroidal Neovascularization
She et al.
IOVS 2007;48:2268-2277.
ABSTRACT | FULL TEXT  

Neurotrophic Factors Minimize the Retinal Toxicity of Verteporfin Photodynamic Therapy
Paskowitz et al.
IOVS 2007;48:430-437.
ABSTRACT | FULL TEXT  

Estimating the yearly number of eyes with treatable neovascular age-related macular degeneration using a direct standardization method and a markov model.
Korobelnik et al.
IOVS 2006;47:4270-4276.
ABSTRACT | FULL TEXT  

Intravitreal Bevacizumab for Choroidal Neovascularization Caused by AMD (IBeNA Study): Results of a Phase 1 Dose-Escalation Study.
Costa et al.
IOVS 2006;47:4569-4578.
ABSTRACT | FULL TEXT  

A 76-year-old man with macular degeneration.
Arroyo
JAMA 2006;295:2394-2406.
FULL TEXT  

A review of developments in the management of retinal diseases.
Banerjee
JRSM 2006;99:125-127.
FULL TEXT  

Ultrahigh resolution optical coherence tomography in non-exudative age related macular degeneration
Pieroni et al.
Br J Ophthalmol 2006;90:191-197.
ABSTRACT | FULL TEXT  

Verteporfin Therapy for Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration: Four-Year Results of an Open-Label Extension of 2 Randomized Clinical Trials: TAP Report No. 7
Treatment of Age-Related Macular Degeneration With
Arch Ophthalmol 2005;123:1283-1285.
FULL TEXT  

Photodynamic therapy with PhotoPoint photosensitiser MV6401, indium chloride methyl pyropheophorbide, achieves selective closure of rat corneal neovascularisation and rabbit choriocapillaris
Ciulla et al.
Br J Ophthalmol 2005;89:113-119.
ABSTRACT | FULL TEXT  

BDNF Reduces the Retinal Toxicity of Verteporfin Photodynamic Therapy
Paskowitz et al.
IOVS 2004;45:4190-4196.
ABSTRACT | FULL TEXT  

A prospective study of visual function and quality of life following PDT in patients with wet age related macular degeneration
Armbrecht et al.
Br J Ophthalmol 2004;88:1270-1273.
ABSTRACT | FULL TEXT  

Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: the UK case
Smith et al.
Br J Ophthalmol 2004;88:1107-1112.
ABSTRACT | FULL TEXT  

Colour vision testing as an aid to diagnosis and management of age related maculopathy
Arden and Wolf
Br J Ophthalmol 2004;88:1180-1185.
ABSTRACT | FULL TEXT  

Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration
Hopley et al.
Br J Ophthalmol 2004;88:982-987.
ABSTRACT | FULL TEXT  

Treatment of age-related macular degeneration
Browning et al.
JRSM 2004;97:166-169.
FULL TEXT  

Photodynamic therapy with verteporfin is effective, but how big is its effect? Results of a systematic review
Meads and Hyde
Br J Ophthalmol 2004;88:212-217.
ABSTRACT | FULL TEXT  

Photodynamic Therapy With Verteporfin in Subfoveal Choroidal Neovascularization Secondary to Central Serous Chorioretinopathy
Ergun et al.
Arch Ophthalmol 2004;122:37-41.
ABSTRACT | FULL TEXT  

Successful photodynamic therapy for subretinal neovascularisation due to Sorsby's fundus dystrophy: 1 year follow up
Wong et al.
Br J Ophthalmol 2003;87:796-797.
FULL TEXT